Bicara CMO reports 175,000 BCAX stock options
Bicara Therapeutics Inc. reported initial insider holdings for Chief Medical Officer William Schelman on a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Bicara Therapeutics Inc. reported initial insider holdings for Chief Medical Officer William Schelman on a Form 3. He holds stock options to acquire 25,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036, and options over 150,000 shares at $16.61 per share, expiring on October 1, 2035. These options vest over time, with one grant vesting 25% on October 1, 2026 and the balance in twelve quarterly installments, and the other vesting in sixteen equal quarterly installments following February 2, 2026, all subject to his continued service.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Schelman William
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 175,000 contracts (Direct)
Footnotes (2)
- F1. 25% of the shares underlying this option vest on October 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option exercise price: $16.76 per share
Underlying shares: 25,000 shares
Option expiration: February 2, 2036
+5 more
8 metrics
Option exercise price
$16.76 per share
Stock option over 25,000 common shares
Underlying shares
25,000 shares
Common stock underlying first option grant
Option expiration
February 2, 2036
Expiry of $16.76 option grant
Option exercise price
$16.61 per share
Stock option over 150,000 common shares
Underlying shares
150,000 shares
Common stock underlying second option grant
Option expiration
October 1, 2035
Expiry of $16.61 option grant
Initial vest date
October 1, 2026
25% vesting for one grant
Vesting structure
16 quarterly installments
Vesting for second option grant after Feb 2, 2026
Key Terms
Stock Option (Right to Buy), Common Stock, vesting, Chief Medical Officer
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Medical Officer financial
"officer_title: Chief Medical Officer"
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Bicara Therapeutics (BCAX) Form 3 for William Schelman show?
The Form 3 shows Chief Medical Officer William Schelman’s initial option holdings, including rights over 25,000 and 150,000 common shares. It establishes his baseline equity position through stock options with specified exercise prices, expirations, and time-based vesting schedules tied to continued service.
What are the exercise prices of William Schelman’s BCAX stock options?
Schelman’s reported options have exercise prices of $16.76 and $16.61 per share. These prices represent the cost per Bicara common share if he chooses to exercise the respective options after they vest, assuming all other conditions in the grants are satisfied.
When do William Schelman’s Bicara Therapeutics options expire?
One option grant expires on February 2, 2036, and the other on October 1, 2035. These expiration dates define the final days by which Schelman may exercise the respective vested options to purchase Bicara common stock under those grants.
How do William Schelman’s BCAX options vest over time?
For one grant, 25% of the underlying shares vest on October 1, 2026, with the rest vesting in twelve equal quarterly installments. The other grant vests in sixteen equal quarterly installments after February 2, 2026, in each case requiring his continued service at every vesting date.
Does the Form 3 for BCAX indicate any recent buying or selling by William Schelman?
The Form 3 summarizes Schelman’s existing stock option holdings and vesting schedules rather than open-market trades. The transactions are categorized as holdings with unknown transaction codes, and there are no reported buy or sell transactions associated with these option positions in the data provided.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates